News
The Phase II EvolvE trial (NCT05774184) confirmed barzolvolimab’s mechanism of action but showed no measurable improvement in dysphagia symptoms or esophageal inflammation in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback